Phathom Pharmaceuticals (PHAT) Income towards Parent Company (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Income towards Parent Company of -$28.0 million for Q2 2026, up 66.44% year-over-year from -$16.8 million in Q2 2025, and up 41.64% quarter-over-quarter from -$48.0 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Income towards Parent Company (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Income towards Parent Company for 9 consecutive years, with -$28.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Income towards Parent Company rose 66.44% year-over-year to -$28.0 million; the TTM figure through Jun 2026 stood at -$152.3 million (up 51.82% YoY), while the FY2025 annual figure was -$458.6 million, up 11.41% from the prior year.
- Income towards Parent Company advanced to -$28.0 million in Q2 2026 per PHAT's latest filing, from -$48.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$19.8 million in Q4 2024 and bottomed at -$118.7 million in Q3 2024.
- Historically, Income towards Parent Company has averaged -$58.7 million across 5 years, with a median of -$49.4 million in 2022.
- On a YoY basis, Income towards Parent Company climbed as much as 79.37% in 2024 and fell as far as 175.73% in 2024.
- Phathom Pharmaceuticals' Income towards Parent Company stood at -$47.4 million in 2022, then tumbled by 102.1% to -$95.9 million in 2023, then soared by 79.37% to -$19.8 million in 2024, then fell by 6.87% to -$21.1 million in 2025, then tumbled by 32.41% to -$28.0 million in 2026.
- Business Quant data shows PHAT's Income towards Parent Company at -$28.0 million in Q2 2026, -$48.0 million in Q1 2026, and -$21.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.00 Mn |
| Mar 31, 2026 | -47.97 Mn |
| Dec 31, 2025 | -10.15 Mn |
| Sep 30, 2025 | -55.21 Mn |
| Jun 30, 2025 | -83.42 Mn |
| Mar 31, 2025 | -94.29 Mn |
| Dec 31, 2024 | -74.50 Mn |
| Sep 30, 2024 | -118.69 Mn |
| Jun 30, 2024 | -91.44 Mn |
| Mar 31, 2024 | -82.81 Mn |
| Dec 31, 2023 | -65.06 Mn |
| Sep 30, 2023 | -43.05 Mn |
| Jun 30, 2023 | -46.29 Mn |
| Mar 31, 2023 | -37.83 Mn |
| Dec 31, 2022 | -67.72 Mn |
| Sep 30, 2022 | -51.08 Mn |
| Jun 30, 2022 | -50.92 Mn |
| Mar 31, 2022 | -40.70 Mn |
| Dec 31, 2021 | -35.81 Mn |
| Sep 30, 2021 | -63.72 Mn |